Regeneron stock: Q3 growth expands Sanofi antibody alliance
Published on 11/02/2026 at 16:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth And Sanofi Alliance Expand
- Third-quarter revenue rose 36 percent to USD 5.116 billion, while adjusted diluted earnings per share increased 70 percent to USD 20.07.
- Regeneron expanded its Sanofi partnership to four next-generation antibodies and expects to recognize a USD 1 billion upfront payment in the fourth quarter.
- EYLEA HD and Libtayo grew strongly, but combined EYLEA and EYLEA HD sales remained under product-mix pressure.
Regeneron reported strong third-quarter results on Friday, October 30, 2026, with revenue up 36 percent year over year to USD 5.116 billion. The company also expanded its antibody partnership with Sanofi, adding four next-generation, long-acting antibodies. The figures and transaction terms were published in Regeneron's investor release.
Stronger Earnings, Broader Pipeline
GAAP diluted earnings per share increased 35 percent to USD 18.45, while adjusted diluted earnings per share rose 70 percent to USD 20.07. Sanofi collaboration revenue climbed 68 percent to USD 2.724 billion, helped by higher antibody commercialization profits after the Sanofi Development Balance was fully repaid at the end of the second quarter.
Product performance was mixed but generally supportive. Dupixent global sales recorded by Sanofi increased 35 percent to USD 6.541 billion. U.S. EYLEA HD sales rose 62 percent to USD 699 million, and global Libtayo sales increased 51 percent to USD 550 million. Combined U.S. sales of EYLEA HD and legacy EYLEA fell 1 percent, showing the pressure from the transition away from the older formulation.
Sanofi Deal Adds Fourth-Quarter Support
Under the expanded alliance, Regeneron received a USD 1 billion upfront payment and may receive up to an additional USD 7 billion in development, regulatory and sales-based milestones. The companies will share development and commercialization costs equally and split future profits equally if the new programs reach the market. Regeneron expects to recognize the upfront payment as collaboration revenue in the fourth quarter of 2026.
Regeneron stock traded at 863.45 euros on Lang & Schwarz at 16:39 CET on Monday, November 2, 2026. That compares with 819.30 euros cited at 16:37 CEST on Friday, October 30, in the previous report, an increase of 5.39 percent.
Regeneron Pharmaceuticals
- ISIN: US75886F1075
- Ticker: REGN
- Home exchange: Nasdaq
- Lang & Schwarz quote: 863.45 euros on November 2, 2026 at 16:39 CET
- Change since prior report: 5.39 percent versus 819.30 euros on October 30, 2026
U.S. biotechnology sentiment and broader risk appetite remain relevant for investors; see current market reports.
